NCT06349473 - A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

April 27, 2026

Study Completion Date

April 27, 2026

Conditions

Healthy ParticipantsHemophilia AHemophilia BFactor VII Deficiency

Interventions

DRUG

SR604

SR604 will be administered as SC injection.

DRUG

Placebo

Placebo will be administered as single SC injection.

Trial Locations (10)

17033

NOT_YET_RECRUITING

Penn State Milton S Hershey Medical Center Pediatrics, Hershey

19104

RECRUITING

Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia

27834

NOT_YET_RECRUITING

Brody School of Medicine at East Carolina University, Greenville

48109

RECRUITING

University of Michigan Hospitals - Michigan Medicine, Ann Arbor

60612

NOT_YET_RECRUITING

Rush University Medical Center, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

70001

RECRUITING

LA Center for Bleeding and Clotting Disorders - Metairie, Metairie

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

91206

COMPLETED

California Clinical Trials Medical Group (CCTMG), Glendale

L8N 3Z5

RECRUITING

McMaster University Medical Centre, Hamilton Health Sciences, Hamilton